Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer

Alexander Glaser,^{1,2,*} Zhuqing Shi,^{1,*} Jun Wei,¹ Nadia A. Lanman,³ Skylar Ladson-Gary,¹
Renee E Vickman,¹ Omar E. Franco,¹ Susan E. Crawford,¹ S. Lilly Zheng,¹ Simon W.
Hayward,¹ William B. Isaacs,⁴ Brian T. Helfand,^{1,2,5†} Jianfeng Xu^{1,2,5†}

¹Program for Personalized Cancer Care, ²Department of Surgery, NorthShore University HealthSystem, Evanston, IL; ³Collaborative Core for Cancer Bioinformatics, Purdue Center for Cancer Research, Purdue University, West Lafayette, IN; ⁴Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine; Baltimore, MD; ⁵Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, IL

*These authors contributed equally to this work.

†Corresponding authors: Jianfeng Xu. 1001 University Place, Evanston, IL 60201, U.S.A.

Phone: (224) 264-7501. Fax: (224) 364-7675. E-mail: jxu@northshore.org

Keywords: Benign prostatic hyperplasia (BPH), prostate cancer, heritability, genetic correlation, SNPs, genetic risk score, lethal

Word count of text: 3,203 words (max 3,500 words)

Word count of the abstract: 300 words (max 300 words)

References: 30 (max 30)

Running Title: Shared inherited genetics of BPH and PCa

Abstract

Background: The association between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) remains controversial, largely due to inherent detection bias in traditional observational studies. The objective of this study is to assess their association using inherited SNPs.

Methods: Subjects were White men from the large population-based UK Biobank (UKB). Association between BPH and PCa was tested: 1) phenotypical correlation using chi-square test, 2) genetic correlation (r_g) based on 1,126,841 polymorphic SNPs across the genome using linkage disequilibrium score regression (LDSR), and 3) cross-disease genetic associations based on known risk-associated SNPs (15 for BPH and 239 for PCa), individually and cumulatively as measured by genetic risk score (GRS).

Findings: Among 214,717 White men in the UKB, 24,623 (11.47%) and 14,311 (6.67%) had a diagnosis of BPH and PCa, respectively. Diagnoses of these two diseases were significantly correlated, $\chi^2=1862.80$, $P<1E-299$. A significant genetic correlation was found, r_g (95% confidence interval (CI))=0.27 (0.15-0.39), $P=9.17E-06$. In addition, significant cross-disease genetic associations for established risk-associated SNPs were also found. Among the 250 established GWAS-significant SNPs of PCa or BPH, 51 were significantly associated with risk of the other disease at $P<0.05$, significantly more than expected by chance ($N=12$), $P=3.04E-7$ (χ^2 -test). Furthermore, significant cross-disease GRS associations were also found; GRS_{BPH} was significantly associated with PCa risk (odds ratio (OR)=1.26 (1.18-1.36), $P=1.62E-10$), and GRS_{PCa} was significantly associated with BPH risk (OR=1.03 (1.02-1.04), $P=8.57E-06$). Moreover, GRS_{BPH} was significantly and inversely associated with lethal PCa risk in a PCa case-case analysis (OR=0.58 (0.41-0.81), $P=1.57E-03$). In contrast, GRS_{PCa} was not significantly associated with lethal PCa (OR=0.99 (0.94-1.04), $P=0.79$).

Interpretation: BPH and PCa share common inherited genetics which suggests the phenotypical association of these two diseases in observational studies is not entirely caused by detection bias. This novel finding may have implications in disease etiology and risk stratification.

Funding: None.

Introduction

Benign prostatic hyperplasia (BPH) is a histological diagnosis characterized by a proliferation of both stromal and epithelial cells in the transitional zone of the prostate.¹ This proliferation can lead to bladder outlet obstruction and subsequent lower urinary tract symptoms (LUTS). Prostate cancer (PCa), on the other hand, is a malignant adenocarcinoma primarily found in the peripheral zone of the prostate and, prior to metastasis is typically asymptomatic being primarily detected by PSA-screening.² BPH and PCa are two of the most common diseases in men and incidence for both conditions increases considerably with age.^{3, 4} These two pathologic processes negatively impact quality of life and result in considerable healthcare expense.

Despite the major differences in cellular growth patterns and stereotyped locations within the prostate, a link between BPH and PCa has been hypothesized, studied and reported.^{5, 6} Their co-occurrence was first documented from autopsy studies in 1957 and 1992.^{7, 8} Since then, conflicting results on the association have been published in multiple epidemiological studies, including those from retrospective case-control studies,^{9, 10} prospective cohorts,¹⁰ secondary analysis of clinical trials,^{11, 12} large population-based cohorts,^{13, 14} and a recent meta-analysis.¹⁵ To date, no consensus has been reached on their association and causal relationship.⁶ Consequently, the current National Cancer Institute website states that 'BPH is not linked to cancer and does not increase your risk of getting PCa'.¹⁶

A major cause for the inconclusive findings is the inherent detection bias of observational studies in diagnosing these two diseases. Patients treated by urologists for one of these diseases (e.g., BPH) are more likely to be examined thoroughly and are therefore more likely to be diagnosed for the other disease (PCa).¹⁷ This detection bias is particularly prominent because the likelihood of diagnosing BPH and PCa increases with heightened prostate examinations and diagnostic evaluations that include prostate-specific antigen (PSA) measurements, which is included in current guidelines for each of these disease states.^{18, 19}

The availability of high-throughput SNP genotyping technology in the last 15 years enabled a systematic evaluation of genetic variants in the genome among large numbers of subjects. This technology advanced the understanding of the polygenic architecture of common diseases in two distinct ways. First, using millions of SNPs in the genome, it is now possible to estimate polygenic heritability of a disease using linkage disequilibrium score regression (LDSR).²⁰ Furthermore, unbiased estimates of SNP-based genetic correlation between two diseases can be obtained using LDSR. Second, it is also feasible to systematically compare genetic variants in the genome in subjects with or without a disease using genome-wide association studies (GWAS) to identify disease risk-associated SNPs. Owing to the rigorous requirement of statistical significance ($P < 2E-08$) and confirmation in independent studies, risk-associated SNPs identified by GWAS most likely represent true associations. To date, 269 and 17 risk-associated SNPs have been identified for PCa and BPH, respectively.^{21, 22} Although the effect of these risk-associated SNPs is moderate individually, they are additive and have a stronger cumulative effect that can be measured by a polygenic risk score. Published studies have consistently demonstrated the performance of polygenic risk score for measuring and stratifying inherited risk.²¹⁻²⁴ Due to the inherited nature of SNPs (fixed at conception and always preceding occurrence of diseases), they are less susceptible to detection bias in assessing associations of two diseases from observational studies.

The primary hypothesis of this study is that BPH and PCa are linked and that this association is partially contributed by shared inherited genetics via the same genes (causal or pleiotropic effects) and/or different genes in linkage disequilibrium (LD). This hypothesis was tested in a large population-based cohort by 1) assessing phenotypical associations between the two diseases, 2) estimating their genetic correlation based on millions of SNPs in the genome using LDSR, and 3) performing cross-disease genetic association tests based on known risk-associated SNPs, individually and cumulatively. Furthermore, the clinical utilities of polygenic risk score of BPH and PCa for predicting the risk of these two diseases were also assessed.

Methods

Subjects

Subjects of this study were from the UK Biobank (UKB), a population-based study with extensive genetic and phenotypic data for approximately 500,000 individuals from across the United Kingdom aged between 40 and 69 at recruitment (accessed under Application Number: 50295).²⁵ Extensive phenotypic and genomic information is available for each participant in the UKB, including disease diagnosis, questionnaire, biological measurements, lifestyle indicators, and biomarkers in blood and urine. Diagnoses of BPH (Data-Field 132073) and the procedure for transurethral resection of the prostate (TURP) (Data-Field 41200, 41210 and 41272), as well as diagnosis of PCa (Data-Field 40001, 40002, 40006, 41202, 41204, 41270) were provided by the UKB based on the ICD-10 code and/or self-reports (released on July 9th, 2021). Information on PCa-specific death (lethal PCa) was based on death registries. Genome-wide SNPs data are available for all participants.

SNPs and polygenic risk score

Independent risk-associated SNPs for BPH and PCa included in this study were established using evidence-based review of published GWAS (defined as $P < 5 \times 10^{-8}$ and pair-wise linkage disequilibrium (LD, $r^2 < 0.2$)) and are available in the UKB, including 15 for BPH and 239 for PCa. Their SNP ID, risk and reference alleles, odds ratio, allele frequency, and references are described in **sTable 1**.

The cumulative effect of SNPs on each disease was measured by genetic risk score (GRS), a population-standardized polygenic risk score. GRS was calculated by multiplying the per-allele odds ratio (OR) with number of risk alleles of each SNP and normalizing the risk by the average risk expected in the population.²⁶ As such, GRS value can be interpreted as relative risk to the general population regardless number of risk-associated SNPs used in GRS calculation.

Statistical analysis

Correlation between BPH and PCa was assessed using a chi-square test. The strength of association (OR and 95% confidence interval (CI)) between the two diseases

was estimated using a multivariable logistic regression adjusting for age at recruitment and genetic background (top 10 principal components provided by the UKB).

SNP-based heritability (h^2) for BPH and PCa, respectively, and genetic correlation (r_g) between BPH and PCa were estimated based on polymorphic SNPs (minor allele frequency >0.01) in the genome using LDSR analysis.²⁰ GWAS summary statistics of BPH and PCa (adjusting for age at recruitment and genetic background) were matched to the pre-computed LD scores of the 1000 Genomes European reference. SNP heritability estimates were converted to the liability-scale based on the observed prevalence in the UKB.

Cross-disease genetic association for BPH and PCa was tested based on known risk-associated SNPs (individually and cumulatively as measured by GRS) of these two diseases. Association of individual SNPs and GRS with cross-disease risk was tested adjusting for age at recruitment and genetic background.

Results

Among 214,717 White men in the UKB, 24,623 (11.47%) and 14,311 (6.67%) had a diagnosis of BPH and PCa, respectively (**Table 1**). Diagnoses of these two diseases were significantly correlated, $\chi^2=1862.80$, $P<1E-299$. Specifically, 3,231 (1.50%) men had a diagnosis of both BPH and PCa, which was significantly higher than the 1,332 (0.62%) expected assuming that the diagnosis of these diseases were independent, $\chi^2=797.96$, $P=1.50E-175$. Having a diagnosis of PCa was associated with an OR (95% CI) of 1.58 (1.51-1.65) for BPH risk, $P=5.13E-94$. Conversely, having a diagnosis of BPH was associated with an OR (95%CI) of 1.57 (1.50-1.64) for PCa risk, $P=1.07E-90$. These ORs were estimated adjusting for age at recruitment and genetic background.

Genetic susceptibility to BPH and PCa was estimated based on polymorphic SNPs across the genome (minor allele frequency >1%). SNP-based heritability (h^2) (95% CI) was 0.09 (0.07-0.11) for BPH ($P=0.005$) and 0.15 (0.12-0.18) for PCa ($P=4.87E-10$) (**Figure 1**). Furthermore, a significant and positive genetic correlation between the two diseases was found, r_g (95% CI) was 0.27 (0.15-0.39), $P=9.17E-06$.

When examining established risk-associated SNPs for BPH and PCa, significant cross-disease genetic associations were found. Among the 250 risk-associated SNPs of PCa or BPH from previous GWAS studies, 51 were significantly associated with risk of the other disease at $P < 0.05$, which was significantly more than expected by chance ($N=12$), $P=3.04E-7$ (χ^2 -test). Specifically, among the 239 established independent PCa risk-associated SNPs, 45 were associated with BPH diagnosis at $P < 0.05$ (**sTable 1**). Reciprocally, among the 15 established independent BPH risk-associated SNPs, 10 were associated with PCa diagnosis at $P < 0.05$. It is noted that 4 established GWAS-significant risk-associated SNPs of PCa and BPH were overlapped.

We also evaluated the cumulative effect of SNPs on disease risk. In addition to highly significant association between disease-specific GRS and their respective disease risks, significant cross-disease associations were also found (**Table 2**). GRS based on the 15 established BPH risk-associated SNPs was positively associated with PCa diagnosis ($OR=1.26$, $P=1.62E-10$). Similarly, GRS based on the 239 established PCa risk-associated SNPs (GRS_{PCa}) was significantly associated with BPH diagnosis ($OR=1.03$, $P=8.57E-06$).

Furthermore, GRS was also associated with specific phenotypes of BPH and PCa (**Table 2**). Notably, GRS_{BPH} was inversely associated with lethal PCa risk when comparing lethal PCa cases vs. non-lethal PCa cases ($OR=0.58$, $P=1.57E-03$). Upon examining results by GRS_{BPH} deciles (**sTable 2**), while no trend of lethal PCa prevalence with GRS_{BPH} deciles was found ($P=0.14$), the prevalence of lethal PCa in men of the highest GRS_{BPH} decile was 0.23%, noticeably lower than that of remaining deciles (0.33%, $P=0.02$). In contrast, the prevalence of non-lethal PCa increased slightly with higher GRS_{BPH} deciles ($P_{trend}=0.01$), with the highest rate (6.64%) found in men of the top GRS_{BPH} decile. As for GRS_{PCa} , no association with lethal PCa was found in a case-case analysis ($OR=0.99$, $P=0.79$). GRS_{PCa} it was not associated with lethal PCa in case-case analysis ($OR=0.99$, $P=0.79$). The prevalence of both lethal PCa and non-lethal PCa increased by each decile at a similar scale (**sTable 2**).

In light of the genetic correlation and cross-disease association of GRS between these two diseases, we next explored the clinical utility of using two GRS values for predicting diagnosis of BPH, PCa, and both diseases (**Table 3, Figure 2**). For example, using a GRS of 1.5 as a cutoff value (i.e., 1.5-fold increased risk over the general population), men

with both high GRS_{BPH} and GRS_{PCa} had a considerably higher prevalence of these two diseases compared to men with both low GRS_{BPH} and GRS_{PCa} ; 15.64% vs. 5.12% for PCa, 16.87% vs. 11.18% for BPH, and 3.76% vs. 1.19% for both BPH and PCa. Similarly, men with either high GRS_{BPH} or GRS_{PCa} had higher prevalence of these two diseases. For lethal PCa, men with low GRS_{BPH} and high GRS_{PCa} had a higher prevalence (0.68%) than those with both low GRS (0.25%) and especially those with high GRS_{BPH} but low GRS_{PCa} (0.11%). Regarding surgical intervention for BPH (TURP), men with high GRS_{BPH} had a higher prevalence of TURP than those with low GRS_{BPH} , regardless of GRS_{PCa} (6.54% and 7.40% for high GRS_{BPH} vs. 3.29% and 3.57% for low GRS_{BPH}).

Discussion

The primary goal of this study is to address the longstanding controversy surrounding the link between BPH and PCa.⁵⁻¹⁵ This clinically important question is complicated primarily by the inherent detection bias in epidemiological studies where patients diagnosed with one disease are typically examined more thoroughly by urologists and therefore have a higher chance of being diagnosed with the other disease.¹⁷ It is practically impossible to estimate the degree (partially or total) of the detection bias contributing to the observed association of BPH and PCa in traditional studies. Utilizing a large population-based cohort of over 200,000 men with diagnostic information for both diseases and genome-wide SNP data, we are able to test the association using both traditional epidemiological and alternative inherited genetic approaches (**Figure 1**). We 1) demonstrated a statistical association of phenotypical diagnoses of BPH and PCa ($P < 1E-299$), 2) revealed a polygenic inherited basis for each of these two diseases (h^2 of 0.09 and 0.16 for BPH and PCa, respectively), and 3) more importantly, the present analysis suggests that these two diseases are genetically correlated and that they share part of a polygenic background ($r_g = 0.27$) and risk-associated SNPs. A genetic correlation measures the proportion of the heritability (h^2) that is shared between two diseases divided by the square root of the product of the heritability for each disease. This alternative inherited genetic approach does not directly test phenotypical co-occurrence of two diseases. Instead, it tests the correlation between heritability of each individual disease which is

estimated only from the respective diseases, and therefore is not susceptible to detection bias. These findings provide strong statistical evidence that diagnoses of BPH and PCa are linked and the excessed concurrence of these two diseases was in part contributed by inherited genetics and not entirely driven by detection bias.

Shared inherited risk between BPH and PCa may arise from several potential sources, including 1) LD of different genes for BPH and PCa in the same chromosomal region, 2) pleiotropy where a single gene or variant affects both BPH and PCa, 3) causal effect where a gene causes a disease first which in turn causes the other disease, and 4) biases from population stratification. While the likelihood for the last source is low because this study was based on White men from a population-based cohort and the analysis adjusted for population stratification, we cannot differentiate among the sources of LD, pleiotropy and causality. Therefore, we can only conclude that shared inherited risk is directly or indirectly associated with both BPH and PCa but does not necessary directly cause these two diseases.

Although Mendelian randomization (MR) analysis is a well-established method utilizing measured inherited germline variations (genetic instruments) to interrogate the causal effect of an exposure on an outcome,²⁷ we did not perform an MR analysis in this study for the following two considerations. First, considering the major difference between the two diseases in pathophysiology (benign proliferation for BPH and malignant growth for PCa), anatomic locations (primarily transition zone for BPH and peripheral zone for PCa), and cell types (epithelial and stromal hyperplasia for BPH; epithelial malignant transformation for PCa), we do not hypothesize that the development of either one of these two diseases is an exposure that causes the other disease. Second, it is challenging to test the validity of key assumptions underlying MR analysis (independent and exclusion).²⁸ The independent assumption states that there are no unmeasured confounders of the associations between genetic variants and outcome. The exclusion restriction assumption requires that the genetic variants affect the outcome only through their effect on the risk factor of interest. Therefore, it is difficult to interpret MR results even if they are statistically significant.

As a comparison, we performed a similar analysis to assess the association and genetic correlation between BPH and another urological cancer (bladder cancer). While the diagnoses of these two diseases were highly correlated ($\chi^2=1615.00$, $P<1E-299$), there was no significant genetic correlation between the two diseases ($r_g=0.01$, $P=0.93$). These results suggest that unlike BPH and PCa where the observed link is partially explained by shared inherited risk, there is no evidence that BPH and bladder share inherited genetic risk. The observed link between BPH and bladder cancer may be largely or completely caused by detection bias.

The finding of shared inherited risk between BPH and PCa from this study may have implications in understanding etiology and clinical utility. For example, identifying commonality of genes in the chromosomal regions that are associated with both BPH and PCa may help to better understand etiology for these two diseases. Toward this effort, we performed a preliminary pathway analysis for the 65 nearest genes in the 51 independent regions associated with both BPH and PCa using KEGG (Kyoto Encyclopedia of Genes and Genomes) (**sTable 3**). These genes are significantly enriched in only one biological pathway, the PCa pathway, $P=0.007$ (Benjamini correction) (**sTable 4**). Five (*AR*, *KLK3*, *TP53*, *FGFR2*, and *NKX3-1*) of the 65 genes (7.69%) are involved in the PCa pathway, significantly more than expected by chance (88 of 6,879 genes (1.28%) in the KEGG are in the PCa pathway). Similar results were found in the Ingenuity Pathway Analysis (version 01-20-04, Qiagen, CA). A major caveat of this analysis is that nearest genes may or may not account for the observed genetic associations, a common challenge for understanding biological mechanisms of GWAS findings.

The genetic correlation between the two diseases, especially cross-disease genetic association, also suggest GRS_{BPH} and GRS_{PCa} may be used in the clinic to stratify risk for these two diseases. For example, men with either or both high GRS_{BPH} and GRS_{PCa} have higher risks for these two diseases, alone or both, and men with high GRS_{BPH} are more likely to undergo surgical intervention. Men identified as high risk for these disease states may benefit from more aggressive screening and/or earlier referral to urologic sub-specialists.

While confirming the previous null result that GRS_{PCa} does not differentiate aggressiveness of the disease in PCa patients,^{21, 24, 29} we obtained a novel finding that

GRS_{BPH} is inversely associated with lethal PCa in a case-case analysis. Specifically, men with the highest GRS_{BPH} decile have lower risk for lethal PCa but similar risk for non-lethal PCa when comparing to men in the remaining deciles. This finding is important and plausible considering that 1) GRS_{BPH} is positively associated with prostate volume,²² and 2) prostate volume is inversely associated with aggressive PCa.³⁰ However, additional studies are needed to confirm this novel finding before exploring its clinical utility. Furthermore, more studies are warranted to understand specific SNPs and genes underlying this association and their biological effects on lethal PCa. Large PCa patient cohorts with germline data, PSA measurement, prostate volume, Gleason grade at time of diagnosis and prostatectomy surgery, as well as long-term disease follow-up are crucial to confirm and understand the association.

Several limitations of this study are noted. First, due to the fact that ~95% of subjects in the UKB are White, our analyses and conclusions were limited to this group only. The generalizability of our finding in other ethnic and racial populations needs to be evaluated. Second, it is recognized that the UKB cohort was included in a previous GWAS that identified BPH risk-associated SNPs.²² Although this may inflate performance of GRS_{BPH} for predicting BPH risk, it has limited impact on the key findings of genetic correlation. Third, a lack of detailed clinical variables relevant to BPH and PCa in this population-based biobank such as PSA measurement, prostate volume, Gleason grade, and quantification of lower urinary tract symptoms hinder more granular analysis and understanding of clinical and genetic associations. Some findings from this study, especially the inverse association between GRS_{BPH} and lethal PCa, should be considered as preliminary. Comprehensive analysis in large and clinically well-characterized urological patient cohorts are needed. Finally, we did not perform functional analysis to investigate the biological mechanism of the genetic associations for both BPH and PCa. This is in part due to the nature of this genetic study where the primary goal is to identify chromosomal regions with statistical evidence for association. More importantly, we recognize the substantial challenges in these functional studies. The chromosomal region for each genetic association is typically large (>500 kb) and many of these regions are outside of coding genes. Nevertheless, we feel genetic association studies provide critical data relevant to

human diseases. Geneticists and biologists can collaborate to understand biological mechanisms of genetic associations.

Conclusions

In conclusion, utilizing genome-wide SNP data from a large population-based cohort demonstrated that BPH and PCa share common polygenic inherited risk. This novel genetic result suggests the excess of co-occurrence of these two diseases is not completely driven by detection bias. The current conclusion that BPH and PCa are not related, as stated by the NCI and other authoritative agencies, may be reconsidered.

Figure legends

Figure 1. Summary of findings for the phenotypic and genetic link between BPH and PCa in White men of the UKB. First, diagnoses of BPH and PCa were significantly correlated (bi-direction arrows on the right side, $P < 1E-299$). Second, inherited polygenic background contributed to the diagnosis of each disease (horizontal arrows, h^2 of 0.09 and 0.16 for BPH and PCa, respectively). Third, polygenic background for BPH and PCa were significantly correlated (bi-direction arrows on the left side, $r_g = 0.27$, $P = 9.17E-06$). Lastly, cross-disease association of established risk-associated SNPs for BPH and PCa (diagonal arrows). These findings provide strong statistical evidence that diagnoses of BPH and PCa are linked and the excessed co-occurrence of these two diseases was in part contributed by inherited genetics and not entirely driven by detection bias.

Figure 2. Pie charts of prevalence for BPH and PCa diagnoses in four groups of men with low (< 1.5) and high (≥ 1.5) GRS_{BPH} and GRS_{PCa} : a) both low, b) low GRS_{BPH} and high GRS_{PCa} , c) high GRS_{BPH} and low GRS_{PCa} , and d) both high. The percentage of men in each GRS group is indicated under each pie chart. Blue, green, and red slices represent the prevalence of PCa, BPH, and both diseases, respectively.

Acknowledgements

We are grateful to the Ellrodt-Schweighauser family for establishing Endowed Chair of Cancer Genomic Research (Xu), and Chez and Melman families for establishing Endowed Chairs of Personalized Prostate Cancer Care (Helfand), as well as the Rob Brooks Fund for Personalized Prostate Cancer Care at NorthShore University HealthSystem.

Author Contributions

Concept and design: Xu, Helfand, Glaser

Data analysis: Shi, Wei, Lanman

Manuscript draft: Xu, Helfand, Glaser

Critical revision of the manuscript for important intellectual content: Glaser, Shi, Wei, Lanman, Ladson-Gary, Vickman, Franco, Crawford, Zheng, Hayward, Isaacs, Helfand, Xu

Supervision: Xu and Helfand

Ethical approval and consent to participate

The UK Biobank was approved by North West – Haydock Research Ethics Committee (REC reference: 16/NW/0274; IRAS project ID: 200778). Data from the UK Biobank was accessed through a Material Transfer Agreement under Application Reference Number: 50295. This study was performed in accordance with the Declaration of Helsinki.

Data availability

The data used in this study is available in the UK Biobank, a publicly available repository. Data was accessed through a Material Transfer Agreement under Application Reference Number: 50295. For additional information, please feel free to contact the corresponding author, Jianfeng Xu, DrPH.

Competing Interests statement

NorthShore University HealthSystem has an agreement with GoPath Laboratories for genetic tests of polygenic risk score.

REFERENCES

1. Roehrborn CG. Pathology of benign prostatic hyperplasia. *Int J Impot Res* **20 Suppl 3**, S11-8 (2008).
2. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. *Am J Surg Pathol* **12** (12), 897-906 (1988).
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. *J Urol* **132** (3), 474-9 (1984).
4. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin* **71** (1), 7-33 (2021).
5. Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. *Eur Urol* **55** (4), 864-73 (2009).
6. Orsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. *Nat Rev Urol* **10** (1), 49-54 (2013).
7. Sommers SC. Endocrine changes with prostatic carcinoma. *Cancer* **10** (2), 345-58 (1957).
8. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. *Cancer* **70** (1 Suppl), 291-301 (1992).
9. Greenwald P, Kirmss V, Polan AK, Dick VS. Cancer of the prostate among men with benign prostatic hyperplasia. *J Natl Cancer Inst* **53** (2), 335-40 (1974).
10. Armenian HK, Lilienfeld AM, Diamond EL, Bross ID. Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. *Lancet* **2** (7873), 115-7 (1974).
11. Thompson IM, Coltman CA, Jr., Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. *Prostate* **33** (3), 217-21 (1997).
12. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med* **362** (13), 1192-202 (2010).
13. Chokkalingam AP, Nyren O, Johansson JE, Gridley G, McLaughlin JK, Adami HO, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. *Cancer* **98** (8), 1727-34 (2003).
14. Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. *Eur Urol* **60** (4), 691-8 (2011).
15. Zhang L, Wang Y, Qin Z, Gao X, Xing Q, Li R, et al. Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis. *J Cancer* **11** (1), 177-89 (2020).
16. National Cancer Institute. Understanding Prostate Changes: A Health Guide for Men 2021. <https://www.cancer.gov/types/prostate/understanding-prostate-changes> (accessed 3 Nov 2021)

17. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. *Am J Med* **104** (6), 517-25 (1998).
18. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. *J Urol* **206** (4), 806-17 (2021).
19. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. *J Natl Compr Canc Netw* **14** (5), 509-19 (2016).
20. Ni G, Moser G, Schizophrenia Working Group of the Psychiatric Genomics C, Wray NR, Lee SH. Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. *Am J Hum Genet* **102** (6), 1185-94 (2018).
21. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nat Genet* **53** (1), 65-75 (2021).
22. Gudmundsson J, Sigurdsson JK, Stefansdottir L, Agnarsson BA, Isaksson HJ, Stefansson OA, et al. Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. *Nat Commun* **9** (1), 4568 (2018).
23. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. *N Engl J Med* **358** (9), 910-9 (2008).
24. Shi Z, Platz EA, Wei J, Na R, Fantus RJ, Wang CH, et al. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. *Eur Urol*, (2020).
25. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562** (7726), 203-9 (2018).
26. Yu H, Shi Z, Wu Y, Wang CH, Lin X, Perschon C, et al. Concept and benchmarks for assessing narrow-sense validity of genetic risk score values. *Prostate* **79** (10), 1099-105 (2019).
27. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* **37** (7), 658-65 (2013).
28. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res* **4**, 186 (2019).
29. Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu Y, et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. *Clin Cancer Res* **14** (18), 5819-24 (2008).
30. Yamashiro JR, de Riese WTW. Any Correlation Between Prostate Volume and Incidence of Prostate Cancer: A Review of Reported Data for the Last Thirty Years. *Res Rep Urol* **13**, 749-57 (2021).

Figure 1

Figure 2

a: Low GRS_{BPH} and low GRS_{PCa}

80.31%

b: Low GRS_{BPH} and high GRS_{PCa}

16.19%

c: High GRS_{BPH} and low GRS_{PCa}

2.84%

d: High GRS_{BPH} and high GRS_{PCa}

0.66%

Table 1. Diagnosis of BPH and PCa among White men in the UKB (N=214,717)

Table 1: Diagnosis of BPH and PCa among white men in the GSK (N = 217,717)			
Diagnosis	No. (%) of men	Median age (IQR), yr	
		At recruitment	Age at diagnosis
BPH			
Any BPH	24,623 (11.47)	63.5 (60.5-66.5)	62.3 (57.31-67.19)
TURP*	5,704 (26.61)	64.5 (61.5-67.5)	61.58 (57.07-66.31)
Non-TURP*	15,833 (73.39)	63.5 (59.5-66.5)	62.57 (57.4-67.41)
PCa			
Any PCa	14,311 (6.67)	63.5 (59.5-66.5)	65.35 (60.08-69.16)
Lethal PCa	692 (4.84)	65.5 (62.5-68.5)	65.5 (61.02-69.46)
Non-lethal PCa	13,619 (95.16)	63.5 (59.5-66.5)	65.33 (60.8-69.12)
Both BPH and PCa	3,231 (1.5)	64.5 (61.5-67.5)	62.57 (58.06-67.12)**
Neither BPH or PCa	179,014 (83.37)	57.5 (49.5-63.5)	\

*Number of subjects with missing data for TURP (49,817)

**Based on earlier age at diagnosis of BPH and PCa

Table 2. Performance of GRS for predicting disease risk in the UK Biobank, N=214,717

GRS (No. risk SNPs)	Comparison	Sample size	Association test*	
			OR (95% CI)	P
BPH (15 SNPs)	BPH vs. controls	24,623 vs 190,094	2.39 (2.26-2.52)	5.23E-211
	BPH-TURP vs. controls	5,704 vs 205,927	3.61 (3.26-3.98)	3.76E-140
	BPH-TURP vs. BPH non-TURP	5,704 vs 15,833	2.01 (1.78-2.26)	9.65E-31
	PCa vs. controls	14,311 vs 200,406	1.26 (1.18-1.36)	1.62E-10
	Lethal PCa vs. controls	692 vs 214,025	0.74 (0.53-1.02)	0.07
	Lethal PCa vs. non-lethal PCa	692 vs 13,619	0.58 (0.41-0.81)	1.57E-03
PCa (239 SNPs)	BPH vs. controls	24,623 vs 190,094	1.03 (1.02-1.04)	8.57E-06
	BPH-TURP vs. controls	5,704 vs 205,927	1.04 (1.02-1.07)	1.02E-03
	BPH-TURP vs. BPH non-TURP	5,704 vs 15,833	1.02 (0.99-1.06)	0.13
	PCa vs. controls	14,311 vs 200,406	1.53 (1.51-1.55)	<1E-299
	Lethal PCa vs. controls	692 vs 214,025	1.25 (1.21-1.29)	2.74E-34
	Lethal PCa vs. non-lethal PCa	692 vs 13,619	0.99 (0.94-1.04)	0.79

*Adjusting for age at recruitment and genetic background (top 10 principal components)

It is made available under a [CC-BY-NC 4.0 International license](#).

sTable 1. Established risk-associated SNPs for BPH and Pca

Reported from published GWAS							Association with BPH in UKB				Association with PCa in UKB			
SNP	CHR	POS	RA	RAF	OR	Reference	RAF		OR (95% CI)	P	RAF		OR (95% CI)	P
							Cases	Controls			Cases	Controls		
BPH														
rs2556378	2	60,762,502	T	0.16	1.12	Gudmundsson J, Nat Commun. 2018	0.17	0.16	1.13 (1.1-1.16)	9.68E-22	0.16	0.16	0.98 (0.95-1.01)	0.25
rs2853677	5	1,287,194	G	0.41	1.09	Gudmundsson J, Nat Commun. 2018	0.61	0.58	1.11 (1.13-1.09)	1.75E-26	0.60	0.59	1.05 (1.07-1.02)	3.70E-04
rs381949	5	1,322,468	G	0.60	1.11	Gudmundsson J, Nat Commun. 2018	0.44	0.42	1.09 (1.07-1.11)	2.66E-19	0.43	0.42	1.04 (1.02-1.07)	8.52E-04
rs10054105	5	110,909,333	T	0.80	1.10	Gudmundsson J, Nat Commun. 2018	0.81	0.80	1.09 (1.12-1.07)	4.02E-13	0.80	0.80	1.02 (1.05-0.99)	0.31
rs677394	5	134,607,559	C	0.91	1.14	Gudmundsson J, Nat Commun. 2018	0.92	0.91	1.13 (1.17-1.1)	4.78E-13	0.91	0.91	1.03 (1.07-0.98)	0.22
rs200476	6	27,768,348	A	0.82	1.14	Gudmundsson J, Nat Commun. 2018	0.82	0.80	1.09 (1.12-1.06)	9.09E-12	0.81	0.80	1.05 (1.09-1.02)	8.37E-04
rs148678804	10	22,427,289	A	0.03	1.27	Gudmundsson J, Nat Commun. 2018	0.04	0.03	1.25 (1.19-1.32)	1.23E-18	0.03	0.03	1 (0.94-1.07)	0.95
rs4548546	10	122,629,579	T	0.33	1.11	Gudmundsson J, Nat Commun. 2018	0.35	0.33	1.1 (1.08-1.12)	2.25E-20	0.34	0.33	1.05 (1.02-1.08)	2.10E-04
rs11199879	10	123,045,212	C	0.24	1.14	Gudmundsson J, Nat Commun. 2018	0.25	0.22	1.15 (1.13-1.18)	1.18E-36	0.22	0.23	0.97 (0.94-1)	0.02
rs72878024	11	199,492	G	0.93	1.18	Gudmundsson J, Nat Commun. 2018	0.93	0.92	1.13 (1.18-1.09)	4.29E-11	0.93	0.92	1.08 (1.13-1.03)	2.19E-03
rs2555019	12	114,668,618	C	0.52	1.08	Gudmundsson J, Nat Commun. 2018	0.55	0.53	1.05 (1.07-1.03)	1.02E-06	0.52	0.54	0.95 (0.97-0.92)	6.46E-06
rs8853	12	115,108,907	C	0.48	1.07	Gudmundsson J, Nat Commun. 2018	0.50	0.49	1.04 (1.02-1.06)	1.04E-04	0.50	0.49	1.03 (1.1-0.5)	0.05
rs1638703	13	51,088,356	C	0.25	1.10	Gudmundsson J, Nat Commun. 2018	0.27	0.25	1.08 (1.05-1.1)	5.91E-11	0.26	0.25	1.03 (1.01-1.06)	0.02
rs11651052	17	36,102,381	G	0.55	1.08	Gudmundsson J, Nat Commun. 2018	0.54	0.52	1.05 (1.07-1.03)	5.32E-07	0.57	0.52	1.21 (1.24-1.18)	4.96E-50
rs9958656	18	19,904,144	T	0.42	1.11	Gudmundsson J, Nat Commun. 2018	0.43	0.41	1.08 (1.06-1.1)	2.14E-15	0.41	0.42	0.96 (0.93-0.98)	6.56E-04
PCa														
rs636291	1	10,556,097	A	0.69	1.18	Al Olama AA, Nat Genet. 2014	0.68	0.67	1.05 (1.07-1.03)	1.11E-05	0.68	0.67	1.03 (1.06-1.01)	0.01
rs10803412	1	16,376,831	C	0.18	1.05	DV Conti, Nat Genet. 2021	0.18	0.18	1.02 (0.99-1.04)	0.19	0.18	0.18	1.05 (1.01-1.08)	0.01
rs17599629	1	150,658,287	G	0.21	1.07	Schumacher FR, Nat Genet. 2018	0.23	0.23	1.01 (0.99-1.03)	0.43	0.24	0.23	1.07 (1.04-1.1)	9.28E-06
rs1811698	1	150,772,613	C	0.90	1.09	DV Conti, Nat Genet. 2021	0.90	0.91	0.99 (1.02-0.95)	0.37	0.91	0.91	1.08 (1.12-1.03)	6.00E-04
rs10127983	1	153,923,276	T	0.30	1.07	DV Conti, Nat Genet. 2021	0.30	0.30	0.99 (0.97-1.01)	0.50	0.30	0.30	1.03 (1.1-0.6)	0.02
rs1218582	1	154,834,183	G	0.43	1.05	Schumacher FR, Nat Genet. 2018	0.44	0.44	1.01 (0.99-1.03)	0.37	0.45	0.44	1.03 (1.01-1.06)	8.91E-03
rs147847496	1	155,118,588	C	0.96	1.17	DV Conti, Nat Genet. 2021	0.97	0.97	1.08 (1.14-1.01)	0.02	0.98	0.97	1.13 (1.22-1.04)	2.81E-03
rs184104770	1	155,690,186	A	0.02	1.17	DV Conti, Nat Genet. 2021	0.02	0.02	1.05 (0.98-1.12)	0.20	0.02	0.02	1.08 (0.99-1.18)	0.08
rs80237341	1	157,119,915	C	0.02	1.14	DV Conti, Nat Genet. 2021	0.02	0.02	1 (0.93-1.08)	0.97	0.02	0.02	1.02 (0.93-1.13)	0.66
rs6660538	1	163,295,678	A	0.36	1.03	DV Conti, Nat Genet. 2021	0.38	0.38	1 (0.98-1.02)	0.91	0.39	0.38	1.04 (1.02-1.07)	1.35E-03
rs4075646	1	167,135,941	T	0.04	1.06	DV Conti, Nat Genet. 2021	0.03	0.04	0.95 (0.9-1)	0.07	0.04	0.04	1.01 (0.94-1.07)	0.89
rs507603	1	179,897,070	A	0.15	1.04	DV Conti, Nat Genet. 2021	0.16	0.16	0.99 (0.96-1.02)	0.42	0.17	0.16	1.03 (1.1-0.7)	0.05
rs34295433	1	183,032,447	CTAAC	0.52	1.04	DV Conti, Nat Genet. 2021	0.55	0.55	0.99 (1.01-0.97)	0.50	0.56	0.55	1.03 (1.06-1.01)	0.01
rs4245739	1	204,518,842	A	0.76	1.10	DV Conti, Nat Genet. 2021	0.73	0.72	1.01 (1.03-0.99)	0.34	0.74	0.72	1.1 (1.13-1.07)	1.49E-11
rs708723	1	205,739,266	C	0.44	1.04	DV Conti, Nat Genet. 2021	0.45	0.45	1 (0.98-1.02)	0.84	0.47	0.45	1.05 (1.03-1.08)	3.24E-05
rs11686272	2	8,598,444	T	0.45	1.05	DV Conti, Nat Genet. 2021	0.45	0.45	1.01 (0.99-1.03)	0.15	0.46	0.45	1.05 (1.02-1.07)	3.76E-04
rs11902236	2	10,117,868	T	0.27	1.07	Eeles RA, Nat Genet. 2013	0.28	0.28	1.03 (1.01-1.05)	0.01	0.28	0.28	1.03 (1.1-0.6)	0.05
rs1990613	2	10,781,975	T	0.49	1.07	DV Conti, Nat Genet. 2021	0.52	0.52	0.99 (1.01-0.97)	0.37	0.53	0.52	1.05 (1.07-1.02)	2.23E-04
rs7602028	2	16,016,503	C	0.72	1.05	DV Conti, Nat Genet. 2021	0.73	0.74	1 (1.02-0.97)	0.64	0.74	0.73	1.02 (1.05-1)	0.11
rs9306894	2	20,878,105	G	0.38	1.08	DV Conti, Nat Genet. 2021	0.36	0.36	1 (0.98-1.02)	0.74	0.37	0.36	1.06 (1.04-1.09)	2.61E-06
rs6738169	2	43,064,555	C	0.71	1.04	DV Conti, Nat Genet. 2021	0.72	0.72	1.02 (1.04-0.99)	0.15	0.73	0.72	1.05 (1.08-1.03)	1.55E-04
rs7591218	2	43,637,998	A	0.32	1.07	DV Conti, Nat Genet. 2021	0.30	0.30	1.01 (0.98-1.03)	0.67	0.32	0.30	1.1 (1.08-1.13)	1.02E-13
rs28514770	2	43,851,282	C	0.72	1.05	DV Conti, Nat Genet. 2021	0.72	0.72	1.01 (1.03-0.99)	0.57	0.73	0.72	1.06 (1.09-1.03)	1.10E-04
rs11125927	2	62,752,975	G	0.11	1.07	DV Conti, Nat Genet. 2021	0.11	0.11	1.01 (0.98-1.04)	0.41	0.12	0.11	1.12 (1.08-1.16)	3.67E-09
rs58235267	2	63,277,843	G	0.47	1.12	DV Conti, Nat Genet. 2021	0.49	0.49	1.01 (0.99-1.03)	0.54	0.52	0.49	1.13 (1.1-1.16)	1.20E-21
rs139283528	2	63,938,756	G	0.98	1.28	DV Conti, Nat Genet. 2021	0.99	0.98	1.02 (1.11-0.95)	0.58	0.99	0.98	1.12 (1.24-1.01)	0.04
rs74702681	2	66,652,885	T	0.02	1.17	DV Conti, Nat Genet. 2021	0.02	0.02	1.05 (0.98-1.11)	0.17	0.03	0.02	1.14 (1.06-1.24)	7.08E-04
rs2028900	2	85,767,735	C	0.57	1.09	DV Conti, Nat Genet. 2021	0.54	0.55	0.98 (1.0-0.96)	0.01	0.57	0.55	1.08 (1.1-1.05)	3.76E-09
rs2165108	2	111,861,993	A	0.04	1.10	DV Conti, Nat Genet. 2021	0.05	0.05	1 (0.96-1.05)	0.90	0.05	0.05	1.05 (1.1-1.1)	0.07
rs11691517	2	111,893,096	T	0.75	1.06	DV Conti, Nat Genet. 2021	0.75	0.75	1 (1.03-0.98)	0.78	0.76	0.75	1.04 (1.07-1.01)	4.74E-03
rs111595856	2	121,103,598	T	0.06	1.09	DV Conti, Nat Genet. 2021	0.06	0.06	1.02 (0.98-1.07)	0.24	0.07	0.06	1.07 (1.02-1.13)	6.33E-03
rs10206072	2	121,373,466	G	0.90	1.05	DV Conti, Nat Genet. 2021	0.90	0.90	1.01 (1.04-0.98)	0.66	0.90	0.90	1.02 (1.07-0.98)	0.23
rs16854905	2	169,012,955	C	0.90	1.06	DV Conti, Nat Genet. 2021	0.91	0.91	1.03 (1.06-0.99)	0.12	0.91	0.91	1.02 (1.06-0.97)	0.46
rs77167534	2	173,319,930	C	0.94	1.27	DV Conti, Nat Genet. 2021	0.94	0.94	1.02 (1.06-0.98)	0.26	0.95	0.94	1.28 (1.36-1.21)	1.53E-18
rs34925593	2	174,234,547	C	0.50	1.05	DV Conti, Nat Genet. 2021	0.48	0.48	1 (0.98-1.02)	0.80	0.49	0.48	1.02 (1.1-0.5)	0.08
rs21861270	2	202,126,615	G	0.75	1.05	DV Conti, Nat Genet. 2021	0.75	0.75	1 (1.02-0.97)	0.76	0.76	0.75	1.07 (1.1-1.04)	5.06E-06
rs12621900	2	208,118,301	C	0.78	1.05	DV Conti, Nat Genet. 2021	0.78	0.78	0.99 (1.01-0.97)	0.33	0.78	0.78	1 (1.03-0.97)	0.96
rs74001374	2	238,411,293	C	0.99	1.13	DV Conti, Nat Genet. 2021	0.99	0.99	1 (1.14-0.88)	0.97	0.99	0.99	0.92 (1.08-0.79)	0.32
rs2292884	2	238,443,226	G	0.23	1.06	DV Conti, Nat Genet. 2021	0.26	0.26	1 (0.98-1.02)	1.00	0.27	0.25	1.07 (1.04-1.1)	8.09E-07
rs77559646	2	242,135,265	A	0.03	1.33	DV Conti, Nat Genet. 2021	0.02	0.02	0.95 (0.89-1.02)	0.17	0.02	0.02	1.17 (1.08-1.27)	1.93E-04
rs2074840	2	242,141,719	C	0.31	1.05	DV Conti, Nat Genet. 2021	0.30	0.30	1 (0.98-1.02)	0.92	0.31	0.30	1.05 (1.02-1.08)	2.79E-04
rs76832527	2	242,157,241	A	0.17	1.12	DV Conti, Nat Genet. 2021	0.18	0.18	0.96 (0.93-0.98)	1.22E-03	0.19	0.18	1.08 (1.04-1.11)	7.32E-06
rs6550593	3	18,738,940	A	0.73	1.03	DV Conti, Nat Genet. 2021	0.73	0.73	0.99 (1.01-0.97)	3.22E-01	0.74	0.73	1.04 (1.07-1.01)	3.27E-03
rs7618603	3	23,153,062	A	0.17	1.06	DV Conti, Nat Genet. 2021	0.17	0.17	1 (0.97-1.02)	9.31E-01	0.18	0.17	1.06 (1.02-1.09)	6.84E-04
rs2660753	3	87,110,674	T	0.12	1.13	Schumacher FR, Nat Genet. 2018	0.10	0.10	1.02 (0.99-1.06)	1.61E-01	0.11	0.10	1.12 (1.08-1.17)	5.12E-09
rs7628934	3	87,175,984	C	0.52	1.10	DV Conti, Nat Genet. 2021	0.50	0.50	1 (0.98-1.					

It is made available under a [CC-BY-NC 4.0 International license](#).

rs147762399	4	152,030,340	T	0.03	1.10	DV Conti, Nat Genet. 2021	0.04	0.04	0.97 (0.92-1.02)	2.15E-01	0.04	0.04	1.08 (1.02-1.15)	7.75E-03
rs2242652	5	1,280,028	G	0.80	1.14	DV Conti, Nat Genet. 2021	0.81	0.81	1 (1.02-0.98)	9.96E-01	0.83	0.81	1.15 (1.19-1.11)	2.39E-17
rs71595003	5	1,292,118	A	0.03	1.19	DV Conti, Nat Genet. 2021	0.03	0.03	0.95 (0.89-1)	6.09E-02	0.03	0.03	1.14 (1.06-1.22)	1.91E-04
rs2736098	5	1,294,086	T	0.26	1.08	DV Conti, Nat Genet. 2021	0.29	0.28	1.08 (1.06-1.11)	2.90E-13	0.30	0.28	1.1 (1.07-1.13)	1.57E-11
rs4975758	5	1,891,174	G	0.49	1.08	DV Conti, Nat Genet. 2021	0.47	0.46	1.02 (1-1.04)	6.14E-02	0.49	0.46	1.12 (1.09-1.15)	1.84E-19
rs10941370	5	37,833,419	T	0.44	1.03	DV Conti, Nat Genet. 2021	0.45	0.45	1 (0.98-1.02)	6.90E-01	0.46	0.45	1.04 (1.02-1.07)	7.32E-04
rs2121875	5	44,365,545	C	0.32	1.05	Schumacher FR, Nat Genet. 2018	0.33	0.33	0.99 (0.97-1.02)	5.98E-01	0.34	0.33	1.05 (1.02-1.07)	5.24E-04
rs9292122	5	56,087,910	A	0.69	1.04	DV Conti, Nat Genet. 2021	0.73	0.73	1.01 (1.03-0.98)	5.97E-01	0.73	0.73	1.04 (1.07-1.01)	9.39E-03
rs10793821	5	133,836,209	T	0.57	1.06	DV Conti, Nat Genet. 2021	0.57	0.56	1.01 (1.03-0.99)	3.64E-01	0.58	0.56	1.07 (1.1-1.04)	2.14E-07
rs9686557	5	172,959,030	C	0.44	1.05	DV Conti, Nat Genet. 2021	0.45	0.45	1 (0.99-1.02)	6.59E-01	0.46	0.45	1.03 (1.01-1.06)	0.02
rs61739424	5	177,683,905	G	0.96	1.10	DV Conti, Nat Genet. 2021	0.96	0.95	1.02 (1.07-0.97)	4.54E-01	0.96	0.95	1.07 (1.14-1.01)	0.02
rs2672843	5	177,891,551	G	0.40	1.05	DV Conti, Nat Genet. 2021	0.41	0.41	1.01 (0.99-1.03)	6.19E-01	0.41	0.41	1.02 (1-1.05)	0.09
rs4976790	5	177,968,915	T	0.11	1.08	Schumacher FR, Nat Genet. 2018	0.12	0.11	1.03 (1-1.06)	4.99E-02	0.12	0.11	1.03 (0.99-1.07)	0.10
rs2814811	6	1,670,985	A	0.39	1.04	DV Conti, Nat Genet. 2021	0.41	0.41	1 (0.98-1.02)	7.95E-01	0.42	0.41	1.04 (1.02-1.07)	1.89E-03
rs2018336	6	11,217,897	T	0.79	1.07	DV Conti, Nat Genet. 2021	0.77	0.77	1 (1.03-0.98)	7.82E-01	0.78	0.77	1.07 (1.11-1.04)	2.22E-06
rs6927369	6	21,330,689	C	0.81	1.05	DV Conti, Nat Genet. 2021	0.80	0.81	0.99 (1.01-0.97)	3.59E-01	0.81	0.80	1.06 (1.09-1.02)	6.50E-04
rs12665509	6	21,878,849	A	0.45	1.04	DV Conti, Nat Genet. 2021	0.45	0.45	1 (0.98-1.02)	8.32E-01	0.46	0.45	1.03 (1-1.05)	0.04
rs7767188	6	30,073,776	A	0.21	1.06	Schumacher FR, Nat Genet. 2018	0.20	0.19	1.01 (0.98-1.03)	6.64E-01	0.20	0.19	1.04 (1.01-1.07)	0.01
rs130067	6	31,118,511	G	0.20	1.05	Kote-Jarai Z, Nat Genet. 2011	0.20	0.20	1.03 (1-1.05)	2.00E-02	0.21	0.20	1.06 (1.03-1.09)	2.35E-04
rs3129859	6	32,400,939	G	0.68	1.06	Schumacher FR, Nat Genet. 2018	0.68	0.68	1.03 (1.05-1.01)	3.59E-03	0.69	0.68	1.08 (1.1-1.05)	6.10E-08
rs9296068	6	32,988,695	T	0.65	1.05	Schumacher FR, Nat Genet. 2018	0.68	0.68	1 (1.02-0.98)	7.70E-01	0.68	0.68	1.01 (1.04-0.99)	0.30
rs9469899	6	34,793,124	A	0.37	1.05	DV Conti, Nat Genet. 2021	0.36	0.36	1.01 (0.99-1.03)	3.05E-01	0.37	0.36	1.04 (1.01-1.06)	7.47E-03
rs4711748	6	43,694,598	T	0.22	1.05	Schumacher FR, Nat Genet. 2018	0.23	0.23	1.01 (0.98-1.03)	5.19E-01	0.23	0.22	1.03 (1-1.06)	0.03
rs9472120	6	43,709,785	C	0.50	1.04	DV Conti, Nat Genet. 2021	0.48	0.47	1.02 (1.01-1.04)	1.50E-02	0.49	0.47	1.05 (1.03-1.08)	3.40E-05
rs9443189	6	76,495,882	A	0.87	1.07	DV Conti, Nat Genet. 2021	0.86	0.86	1 (1.03-0.97)	9.39E-01	0.86	0.86	1.03 (1.07-1)	0.09
rs2038542	6	109,295,293	C	0.15	1.08	DV Conti, Nat Genet. 2021	0.14	0.14	0.98 (0.96-1.01)	1.97E-01	0.15	0.14	1.07 (1.03-1.11)	9.90E-05
rs339331	6	117,210,052	T	0.68	1.09	Schumacher FR, Nat Genet. 2018	0.70	0.69	1.04 (1.06-1.01)	1.03E-03	0.72	0.69	1.13 (1.16-1.1)	6.85E-20
rs13215045	6	153,447,516	C	0.67	1.08	DV Conti, Nat Genet. 2021	0.70	0.70	1.02 (1.04-1)	9.18E-02	0.71	0.70	1.07 (1.09-1.04)	3.63E-06
rs963800	6	160,150,279	C	0.79	1.06	DV Conti, Nat Genet. 2021	0.78	0.78	1 (1.03-0.98)	7.53E-01	0.79	0.78	1.01 (1.04-0.98)	0.39
rs9364554	6	160,833,664	T	0.27	1.11	Schumacher FR, Nat Genet. 2018	0.30	0.30	0.99 (0.97-1.01)	1.67E-01	0.32	0.30	1.09 (1.06-1.12)	3.30E-11
rs138004030	6	170,475,879	G	0.94	1.27	Schumacher FR, Nat Genet. 2018	0.93	0.93	0.99 (1.02-0.95)	4.55E-01	0.93	0.93	1.02 (1.07-0.97)	0.44
rs4513875	7	1,928,159	T	0.38	1.04	DV Conti, Nat Genet. 2021	0.40	0.40	1 (0.98-1.02)	9.23E-01	0.41	0.40	1.03 (1.01-1.06)	0.02
rs35389879	7	21,812,043	T	0.43	1.04	DV Conti, Nat Genet. 2021	0.42	0.41	1.03 (1.01-1.05)	9.90E-03	0.41	0.41	1.01 (0.99-1.04)	0.35
rs10486567	7	27,976,563	G	0.77	1.12	DV Conti, Nat Genet. 2021	0.77	0.77	1.02 (1.04-1)	1.08E-01	0.79	0.77	1.14 (1.17-1.1)	2.73E-17
rs17621345	7	40,875,192	A	0.74	1.07	Schumacher FR, Nat Genet. 2018	0.75	0.75	1.03 (1.05-1)	2.81E-02	0.76	0.75	1.05 (1.08-1.02)	1.39E-03
rs834608	7	47,451,918	A	0.60	1.05	DV Conti, Nat Genet. 2021	0.58	0.58	1 (1.02-0.98)	9.41E-01	0.59	0.57	1.06 (1.08-1.03)	2.08E-05
rs6955627	7	92,577,760	C	0.90	1.05	DV Conti, Nat Genet. 2021	0.92	0.92	0.95 (0.98-0.91)	1.83E-03	0.93	0.92	1.05 (1.1-1)	0.05
rs6465657	7	97,816,327	C	0.48	1.11	Schumacher FR, Nat Genet. 2018	0.46	0.47	0.99 (0.97-1.01)	4.25E-01	0.49	0.46	1.1 (1.07-1.13)	1.53E-14
rs870167	8	8,498,803	G	0.06	1.06	DV Conti, Nat Genet. 2021	0.07	0.07	1.01 (0.97-1.05)	6.38E-01	0.08	0.07	1.13 (1.08-1.19)	8.31E-08
rs2928679	8	23,438,975	A	0.43	1.05	Schumacher FR, Nat Genet. 2018	0.48	0.47	1.05 (1.03-1.07)	2.64E-06	0.48	0.47	1.05 (1.03-1.08)	3.72E-05
rs1160267	8	23,529,521	G	0.43	1.15	DV Conti, Nat Genet. 2021	0.43	0.42	1.03 (1.02-1.05)	5.99E-04	0.45	0.42	1.13 (1.11-1.16)	5.46E-24
rs11135910	8	25,892,142	T	0.15	1.08	Schumacher FR, Nat Genet. 2018	0.17	0.17	1.02 (1-1.05)	7.11E-02	0.18	0.17	1.09 (1.06-1.13)	8.21E-08
rs12677206	8	26,063,165	A	0.33	1.04	DV Conti, Nat Genet. 2021	0.33	0.34	0.98 (0.96-1)	9.22E-02	0.34	0.34	1.03 (1.01-1.06)	9.99E-03
rs11467	8	38,644,914	A	0.62	1.04	DV Conti, Nat Genet. 2021	0.62	0.62	1 (1.02-0.98)	7.22E-01	0.62	0.62	1.02 (1.05-1)	0.12
rs73700335	8	108,923,107	G	0.85	1.05	DV Conti, Nat Genet. 2021	0.84	0.84	0.99 (1.02-0.97)	4.58E-01	0.85	0.84	1.04 (1.07-1)	0.03
rs12543663	8	127,924,659	C	0.31	1.12	Schumacher FR, Nat Genet. 2018	0.31	0.31	0.99 (0.97-1.01)	1.71E-01	0.33	0.31	1.09 (1.07-1.12)	1.78E-11
rs7463326	8	128,027,954	G	0.76	1.17	DV Conti, Nat Genet. 2021	0.75	0.76	0.99 (1.01-0.97)	2.68E-01	0.78	0.75	1.14 (1.18-1.11)	2.70E-19
rs77541621	8	128,077,146	A	0.02	1.89	DV Conti, Nat Genet. 2021	0.02	0.02	0.97 (0.91-1.03)	3.43E-01	0.04	0.02	1.8 (1.69-1.92)	3.41E-75
rs1016343	8	128,093,297	T	0.21	1.25	Hoffmann TJ, Cancer Discov. 2015	0.21	0.20	1.03 (1.01-1.06)	4.87E-03	0.24	0.20	1.24 (1.2-1.27)	8.46E-49
rs13252298	8	128,095,156	A	0.70	1.19	Al Olama AA, Nat Genet. 2009	0.71	0.70	1 (1.02-0.98)	8.71E-01	0.74	0.71	1.14 (1.17-1.11)	9.36E-20
rs78809737	8	128,104,218	G	0.96	1.08	DV Conti, Nat Genet. 2021	0.96	0.95	1.04 (1.09-0.99)	1.08E-01	0.96	0.95	1.29 (1.38-1.21)	1.55E-14
rs16902094	8	128,320,346	G	0.16	1.21	Gudmundsson J, Nat Genet. 2009	0.14	0.14	1.02 (1-1.05)	1.10E-01	0.16	0.14	1.16 (1.12-1.2)	7.12E-19
rs620861	8	128,335,673	G	0.64	1.15	Schumacher FR, Nat Genet. 2018	0.64	0.63	1.03 (1.05-1.01)	8.58E-04	0.66	0.63	1.14 (1.17-1.11)	3.31E-24
rs6983267	8	128,413,305	G	0.51	1.18	DV Conti, Nat Genet. 2021	0.53	0.52	1.07 (1.09-1.05)	1.31E-11	0.57	0.52	1.26 (1.29-1.23)	4.67E-78
rs11986220	8	128,531,689	A	0.11	1.56	Hoffmann TJ, Cancer Discov. 2015	0.10	0.10	0.96 (0.93-0.99)	1.01E-02	0.13	0.10	1.41 (1.36-1.46)	1.40E-76
rs34265760	8	128,535,543	T	0.98	1.08	DV Conti, Nat Genet. 2021	0.98	0.98	1 (1.07-0.93)	9.85E-01	0.98	0.98	1.05 (1.15-0.96)	0.30
rs12549761	8	128,540,776	C	0.89	1.20	DV Conti, Nat Genet. 2021	0.88	0.88	1 (1.03-0.97)	9.38E-01	0.90	0.88	1.23 (1.28-1.18)	7.05E-25
rs34540271	9	18,554,773	C	0.70	1.05	DV Conti, Nat Genet. 2021	0.69	0.70	0.98 (1-0.96)	8.28E-02	0.70	0.70	1.03 (1.05-1)	0.05
rs1048169	9	19,055,965	C	0.38	1.06	Schumacher FR, Nat Genet. 2018	0.39	0.39	1 (0.98-1.02)	6.45E-01	0.40	0.39	1.05 (1.02-1.07)	5.82E-04
rs1764493	9	22,041,998	G	0.14	1.08	DV Conti, Nat Genet. 2021	0.13	0.13	0.97 (0.95-1)	5.26E-02	0.14	0.13	1.03 (0.99-1.06)	0.16
rs10122495	9	34,049,779	T	0.32	1.06	DV Conti, Nat Genet. 2021	0.28	0.28	0.99 (0.97-1.02)	5.51E-01	0.29	0.28	1.03 (1.01-1.06)	0.02
rs4451364	9	109,532,734	A	0.78	1.05	DV Conti, Nat Genet. 2021	0.75	0.74	1.04 (1.07-1.02)	1.69E-04	0.75	0.74	1.05 (1.08-1.02)	4.57E-04
rs817872	9	110,144,887	C	0.28	1.07	DV Conti, Nat Genet. 2021	0.29	0.29	1.01 (0.99-1.03)	4.06E-01	0.30	0.29	1.07 (1.04-1.1)	1.54E-06
rs143655302	9	110,290,217	G	0.98	1.30	DV Conti, Nat Genet. 2021	0.98	0.98	0.97 (1.04-0.91)	4.32E-01	0.98	0.98	1.24 (1.37-1.12)	1.73E-05
rs2241167	9	130,430,116	A	0.51	1.04	DV Conti, Nat Genet. 2021	0.54	0.55	1 (1.01-0.98)	6.03E-01	0.55	0.54	1.01 (1.04-0.99)	0.29
rs12634	9	132,573,536	T	0.23	1.06	DV Conti, Nat Genet. 2021	0.24	0.24	1.02 (0.99-1.04)	1.96E-01	0.25	0.24	1.04 (1.01-1.07)	3.67E-03
rs141536087	10	854,691	GCGC	0.27	1.08	Schumacher FR, Nat Genet. 2018	0.16	0.16	1.01 (0.98-1.03)	6.14E-01	0.17	0.16	1.04 (1-1.07)	0.04
rs7075427	10	46,104,943	A	0.91	1.13	DV Conti, Nat Genet. 2021	0.91	0.91	0.99 (1.02-0.95)	3.79E-01	0.92	0.91	1.09 (1.14-1.04)	1.08E-04
rs11599847														

It is made available under a [CC-BY-NC 4.0 International license](#).

rs56159348	11	76,267,331	T	0.69	1.06	DV Conti, Nat Genet. 2021	0.68	0.68	1 (1.02-0.98)	8.22E-01	0.69	0.68	1.03 (1.06-1.01)	0.01
rs11568818	11	102,401,661	T	0.57	1.07	DV Conti, Nat Genet. 2021	0.54	0.55	0.99 (1.01-0.97)	1.55E-01	0.57	0.55	1.09 (1.12-1.06)	1.30E-11
rs1800057	11	108,143,456	G	0.02	1.16	Schumacher FR, Nat Genet. 2018	0.03	0.03	1.04 (0.98-1.1)	2.13E-01	0.03	0.03	1.1 (1.02-1.18)	0.01
rs11214775	11	113,807,181	G	0.72	1.07	Schumacher FR, Nat Genet. 2018	0.72	0.72	1 (1.02-0.98)	8.81E-01	0.73	0.72	1.05 (1.08-1.02)	8.89E-04
rs138466039	11	125,054,793	T	0.01	1.32	DV Conti, Nat Genet. 2021	0.01	0.01	0.96 (0.88-1.04)	3.15E-01	0.02	0.01	1.33 (1.21-1.47)	5.76E-09
rs878987	11	134,266,372	G	0.16	1.07	DV Conti, Nat Genet. 2021	0.15	0.16	0.97 (0.95-1)	3.38E-02	0.16	0.16	1.04 (1.01-1.08)	0.01
rs2066827	12	12,871,099	T	0.77	1.06	DV Conti, Nat Genet. 2021	0.77	0.77	1.01 (1.04-0.99)	1.99E-01	0.77	0.77	1.05 (1.08-1.12)	2.25E-03
rs77216612	12	12,877,983	A	0.74	1.03	DV Conti, Nat Genet. 2021	0.72	0.71	1.02 (1.04-1)	1.24E-01	0.72	0.71	1.02 (1.05-0.99)	0.21
rs10845938	12	14,416,918	G	0.58	1.06	DV Conti, Nat Genet. 2021	0.54	0.55	0.98 (1-0.96)	2.91E-02	0.55	0.54	1.04 (1.07-1.02)	7.16E-04
rs80130819	12	48,419,618	A	0.91	1.10	DV Conti, Nat Genet. 2021	0.92	0.92	0.98 (1.02-0.95)	3.22E-01	0.93	0.92	1.1 (1.15-1.05)	7.66E-05
rs56222401	12	49,672,714	G	0.27	1.08	DV Conti, Nat Genet. 2021	0.25	0.25	1 (0.98-1.03)	8.11E-01	0.26	0.25	1.08 (1.05-1.11)	2.61E-07
rs113925811	12	53,308,932	A	0.12	1.18	DV Conti, Nat Genet. 2021	0.11	0.11	1.01 (0.98-1.04)	5.68E-01	0.13	0.11	1.18 (1.14-1.23)	1.23E-18
rs7968403	12	65,012,824	T	0.65	1.06	DV Conti, Nat Genet. 2021	0.63	0.63	1.01 (1.03-0.99)	5.11E-01	0.65	0.63	1.06 (1.09-1.04)	3.36E-06
rs5799921	12	90,160,530	GA	0.70	1.06	Schumacher FR, Nat Genet. 2018	0.72	0.72	1.01 (1.03-0.99)	5.71E-01	0.73	0.72	1.06 (1.09-1.03)	2.02E-05
rs77121786	12	102,446,675	G	0.21	1.05	DV Conti, Nat Genet. 2021	0.20	0.20	0.99 (0.97-1.01)	4.15E-01	0.21	0.20	1.04 (1.01-1.07)	0.01
rs1270884	12	114,685,571	A	0.49	1.07	DV Conti, Nat Genet. 2021	0.47	0.48	0.95 (0.93-0.97)	2.13E-07	0.49	0.48	1.05 (1.03-1.08)	3.49E-05
rs7295014	12	133,067,989	G	0.33	1.05	DV Conti, Nat Genet. 2021	0.33	0.33	1.01 (0.98-1.03)	6.31E-01	0.35	0.33	1.08 (1.06-1.11)	6.91E-10
rs1327653	13	51,076,440	T	0.25	1.04	DV Conti, Nat Genet. 2021	0.26	0.25	1.07 (1.05-1.1)	1.34E-10	0.26	0.25	1.04 (1.01-1.07)	0.01
rs7489409	13	73,716,861	C	0.19	1.07	DV Conti, Nat Genet. 2021	0.19	0.19	0.99 (0.97-1.02)	6.75E-01	0.20	0.19	1.08 (1.05-1.12)	3.41E-07
rs7336001	13	73,995,877	G	0.89	1.11	DV Conti, Nat Genet. 2021	0.92	0.92	1 (1.04-0.97)	9.62E-01	0.92	0.92	1.09 (1.14-1.04)	1.73E-04
rs1004030	14	23,305,649	T	0.58	1.05	DV Conti, Nat Genet. 2021	0.57	0.57	0.99 (1.01-0.97)	2.27E-01	0.58	0.57	1.04 (1.07-1.02)	6.42E-04
rs6571758	14	37,136,194	G	0.62	1.06	DV Conti, Nat Genet. 2021	0.63	0.63	1 (1.02-0.98)	9.20E-01	0.64	0.63	1.05 (1.07-1.02)	4.29E-04
rs11849126	14	38,144,592	G	0.69	1.04	DV Conti, Nat Genet. 2021	0.70	0.70	0.99 (1.01-0.97)	2.76E-01	0.71	0.70	1.04 (1.07-1.01)	4.24E-03
rs8008270	14	53,372,330	C	0.81	1.09	Schumacher FR, Nat Genet. 2018	0.82	0.82	1.01 (1.03-0.98)	5.23E-01	0.83	0.81	1.11 (1.14-1.07)	4.29E-10
rs8005621	14	61,106,699	G	0.08	1.06	DV Conti, Nat Genet. 2021	0.10	0.10	1.02 (0.99-1.05)	2.19E-01	0.10	0.10	1.06 (1.02-1.1)	3.57E-03
rs2093202	14	68,923,908	A	0.61	1.04	DV Conti, Nat Genet. 2021	0.60	0.60	1 (1.02-0.98)	9.17E-01	0.60	0.60	1.03 (1.05-1)	0.05
rs767127	14	69,134,264	G	0.49	1.05	DV Conti, Nat Genet. 2021	0.51	0.50	1.01 (1.03-0.99)	4.48E-01	0.52	0.50	1.05 (1.08-1.03)	1.88E-05
rs8014671	14	71,092,256	G	0.60	1.05	Schumacher FR, Nat Genet. 2018	0.59	0.59	1 (1.02-0.98)	7.86E-01	0.61	0.59	1.07 (1.09-1.04)	6.47E-07
rs11561564	15	40,965,044	G	0.86	1.07	DV Conti, Nat Genet. 2021	0.85	0.85	1.01 (1.04-0.99)	3.55E-01	0.85	0.85	1.05 (1.09-1.02)	4.16E-03
rs33984059	15	56,385,868	A	0.98	1.19	DV Conti, Nat Genet. 2021	0.97	0.97	1.06 (1.13-1)	5.47E-02	0.98	0.97	1.16 (1.25-1.07)	3.24E-04
rs74634457	15	66,835,704	G	0.28	1.05	DV Conti, Nat Genet. 2021	0.25	0.25	1.02 (1-1.04)	7.58E-02	0.26	0.25	1.05 (1.02-1.08)	4.89E-04
rs12913603	15	70,668,824	A	0.41	1.04	DV Conti, Nat Genet. 2021	0.49	0.49	1.02 (1-1.04)	2.04E-02	0.50	0.49	1.03 (1.01-1.06)	8.47E-03
rs7188897	16	54,469,331	T	0.36	1.05	DV Conti, Nat Genet. 2021	0.35	0.35	1.01 (0.99-1.03)	3.94E-01	0.36	0.35	1.03 (1.01-1.06)	0.02
rs13380763	16	54,678,305	C	0.82	1.05	DV Conti, Nat Genet. 2021	0.81	0.81	0.99 (1.02-0.97)	6.41E-01	0.81	0.81	1.04 (1.07-1.01)	0.01
rs11863709	16	57,654,576	C	0.97	1.15	DV Conti, Nat Genet. 2021	0.96	0.96	0.94 (0.99-0.9)	2.48E-02	0.96	0.96	1.02 (1.09-0.96)	0.55
rs28709974	16	79,847,632	C	0.06	1.09	DV Conti, Nat Genet. 2021	0.05	0.04	1.08 (1.03-1.13)	7.73E-04	0.05	0.04	1.12 (1.06-1.18)	1.27E-04
rs8052913	16	82,166,181	C	0.39	1.04	DV Conti, Nat Genet. 2021	0.40	0.39	1.04 (1.02-1.06)	3.00E-04	0.40	0.39	1.04 (1.02-1.07)	1.42E-03
rs684232	17	618,965	C	0.36	1.09	DV Conti, Nat Genet. 2021	0.35	0.36	1 (0.98-1.02)	7.51E-01	0.37	0.35	1.09 (1.06-1.12)	3.17E-11
rs78378222	17	7,571,752	G	0.02	1.26	DV Conti, Nat Genet. 2021	0.01	0.01	1.15 (1.05-1.25)	1.78E-03	0.01	0.01	1.26 (1.13-1.39)	1.40E-05
rs28441558	17	7,803,118	C	0.06	1.17	DV Conti, Nat Genet. 2021	0.06	0.06	1.01 (0.97-1.06)	4.85E-01	0.07	0.06	1.18 (1.13-1.24)	9.59E-12
rs72811270	17	12,585,459	A	0.11	1.06	DV Conti, Nat Genet. 2021	0.12	0.12	1.06 (1.03-1.09)	7.13E-05	0.13	0.12	1.09 (1.05-1.13)	4.32E-06
rs142444269	17	30,098,749	C	1.00	1.07	Schumacher FR, Nat Genet. 2018	0.80	0.81	0.98 (1.01-0.96)	2.12E-01	0.81	0.81	1.03 (1.07-1)	0.04
rs3110641	17	36,047,417	A	0.22	1.06	DV Conti, Nat Genet. 2021	0.22	0.22	1 (0.97-1.02)	7.07E-01	0.22	0.22	1.05 (1.02-1.08)	7.06E-04
rs11649743	17	36,074,979	G	0.82	1.10	DV Conti, Nat Genet. 2021	0.82	0.82	1.04 (1.06-1.01)	7.09E-03	0.84	0.82	1.14 (1.18-1.11)	2.37E-15
rs11263763	17	36,103,565	A	0.55	1.22	DV Conti, Nat Genet. 2021	0.53	0.52	1.05 (1.07-1.03)	4.45E-07	0.57	0.52	1.21 (1.24-1.18)	1.34E-50
rs11650494	17	47,345,186	A	0.07	1.10	Schumacher FR, Nat Genet. 2018	0.09	0.09	1 (0.97-1.04)	8.27E-01	0.10	0.09	1.13 (1.09-1.18)	3.91E-09
rs2960158	17	47,380,305	T	0.77	1.04	DV Conti, Nat Genet. 2021	0.77	0.77	0.98 (1.01-0.96)	1.49E-01	0.77	0.77	1.01 (1.03-0.98)	0.73E-03
rs2680708	17	56,456,120	G	0.60	1.05	Schumacher FR, Nat Genet. 2018	0.61	0.61	1 (1.02-0.99)	6.48E-01	0.62	0.61	1.03 (1.06-1.01)	0.01
rs1859962	17	69,108,753	G	0.49	1.17	Schumacher FR, Nat Genet. 2018	0.47	0.47	0.99 (0.97-1.01)	2.48E-01	0.50	0.47	1.14 (1.12-1.17)	2.01E-27
rs8093601	18	51,772,473	C	0.43	1.05	Schumacher FR, Nat Genet. 2018	0.44	0.43	1.02 (1-1.04)	7.62E-02	0.44	0.43	1.02 (0.99-1.04)	0.17
rs28607662	18	53,230,859	C	0.09	1.08	Schumacher FR, Nat Genet. 2018	0.09	0.09	0.94 (0.91-0.97)	4.60E-04	0.09	0.09	0.99 (0.95-1.04)	0.71
rs35283980	18	56,745,999	G	0.30	1.05	DV Conti, Nat Genet. 2021	0.30	0.30	1.01 (0.99-1.03)	5.30E-01	0.30	0.30	1.01 (0.98-1.04)	0.53
rs11876000	18	73,035,513	T	0.43	1.04	DV Conti, Nat Genet. 2021	0.41	0.41	1 (0.98-1.02)	8.21E-01	0.42	0.41	1.04 (1.01-1.07)	2.61E-03
rs9959454	18	76,770,820	A	0.74	1.09	DV Conti, Nat Genet. 2021	0.73	0.73	1 (1.02-0.98)	8.59E-01	0.74	0.73	1.06 (1.09-1.03)	1.13E-05
rs11666569	19	17,214,073	C	0.72	1.05	Schumacher FR, Nat Genet. 2018	0.71	0.71	0.99 (1.01-0.97)	3.37E-01	0.72	0.71	1.07 (1.1-1.04)	4.18E-06
rs118005503	19	32,167,803	G	0.88	1.09	Schumacher FR, Nat Genet. 2018	0.92	0.92	0.99 (1.02-0.96)	5.12E-01	0.92	0.92	1.05 (1.1-1.01)	0.02
rs59710626	19	38,548,094	G	0.87	1.06	DV Conti, Nat Genet. 2021	0.86	0.86	0.99 (1.01-0.96)	2.87E-01	0.86	0.86	1.02 (1.05-0.98)	0.37
rs4802297	19	38,738,130	G	0.50	1.10	DV Conti, Nat Genet. 2021	0.49	0.48	1.02 (1-1.04)	7.53E-02	0.51	0.48	1.11 (1.08-1.13)	7.80E-16
rs11672691	19	41,985,587	G	0.74	1.10	Schumacher FR, Nat Genet. 2018	0.75	0.75	0.98 (1-0.96)	6.56E-02	0.76	0.75	1.07 (1.1-1.04)	1.26E-06
rs61088131	19	42,700,947	T	0.84	1.06	Schumacher FR, Nat Genet. 2018	0.83	0.83	0.99 (1.01-0.96)	2.73E-01	0.83	0.83	1.01 (1.05-0.98)	0.49
rs61752561	19	51,361,382	G	0.96	1.16	DV Conti, Nat Genet. 2021	0.96	0.96	1.03 (1.08-0.99)	1.78E-01	0.96	0.96	1.1 (1.17-1.04)	2.08E-03
rs76765083	19	51,362,715	T	0.93	1.31	DV Conti, Nat Genet. 2021	0.93	0.93	1.07 (1.11-1.03)	2.45E-04	0.95	0.93	1.43 (1.51-1.35)	2.39E-39
rs11480453	20	31,347,512	C	0.58	1.04	DV Conti, Nat Genet. 2021	0.60	0.60	1.01 (1.03-0.99)	3.19E-01	0.61	0.60	1.03 (1.05-1)	0.04
rs6141551	20	34,006,970	C	0.61	1.04	DV Conti, Nat Genet. 2021	0.63	0.63	1.01 (1.03-0.99)	3.24E-01	0.64	0.63	1.04 (1.07-1.02)	1.55E-03
rs73909841	20	49,548,807	T	0.93	1.11	DV Conti, Nat Genet. 2021	0.93	0.93	1.03 (1.07-0.99)	1.31E-01	0.93	0.93	1.07 (1.13-1.02)	4.46E-03
rs6126986	20	52,464,719	C	0.48	1.07	DV Conti, Nat Genet. 2021	0.49	0.49	1 (0.98-1.02)	8.12E-01	0.50	0.49	1.05 (1.03-1.08)	4.44E-05
rs2427345	20	61,015,611	C	0.63	1.05	Schumacher FR, Nat Genet. 2018	0.63	0.63	1.04 (1.06-1.02)	1.45E-04	0.63	0.63	1.02 (1.05-1)	0.10
rs381331	20	62,229,989	A	0.62	1.05	DV Conti, Nat Genet. 2021	0.61	0.61	0.99 (1.01-0.97)	5.06E-01	0.62	0.61	1.06 (1.09-1.04)	1.

sTable 2. Prevalence of lethal and non-lethal PCa by GRS deciles

GRS (range)	No.	Lethal PCa			Non-lethal PCa		
		No.	%	P-trend	No.	%	P-trend
GRS _{BPH}				0.14			0.01
(0,0.704]	19,783	61	0.31%		1,183	5.98%	
(0.704,0.783]	19,780	62	0.31%		1,190	6.02%	
(0.783,0.845]	19,792	81	0.41%		1,248	6.31%	
(0.845,0.902]	19,784	62	0.31%		1,265	6.39%	
(0.902,0.96]	19,770	66	0.33%		1,267	6.41%	
(0.96,1.02]	19,782	59	0.30%		1,283	6.49%	
(1.02,1.09]	19,779	67	0.34%		1,241	6.27%	
(1.09,1.18]	19,786	64	0.32%		1,305	6.60%	
(1.18,1.31]	19,779	63	0.32%		1,210	6.12%	
(1.31,3]	19,775	45	0.23%		1,313	6.64%	
GRS _{PCa}				7.64E-47			<1E-299
(0,0.242]	20,939	17	0.08%		330	1.58%	
(0.242,0.343]	20,939	28	0.13%		605	2.89%	
(0.343,0.443]	20,938	41	0.20%		737	3.52%	
(0.443,0.551]	20,939	44	0.21%		867	4.14%	
(0.551,0.677]	20,938	64	0.31%		1,026	4.90%	
(0.677,0.831]	20,939	49	0.23%		1,203	5.75%	
(0.831,1.04]	20,938	75	0.36%		1,429	6.82%	
(1.04,1.36]	20,939	80	0.38%		1,707	8.15%	
(1.36,1.97]	20,938	108	0.52%		2,124	10.14%	
(1.97,51]	20,939	161	0.77%		3,259	15.56%	

It is made available under a [CC-BY-NC 4.0 International license](#).

sTable 3. Nearest genes in the chromosomal regions that are associated with both BPH and PCa risk

rsID	CHR	Position	Nearest genes	Gene Name
rs636291	1	10,556,097	PEX14	peroxisomal biogenesis factor 14(PEX14)
rs147847496	1	155,118,588	DPM3	dolichyl-phosphate mannosyltransferase subunit 3(DPM3)
rs11902236	2	10,117,868	GRHL1	grainyhead like transcription factor 1(GRHL1)
rs2028900	2	85,767,735	MAT2A	methionine adenosyltransferase 2A(MAT2A)
rs76832527	2	242,157,241	ANO7	anoctamin 7(ANO7)
rs2811476	3	127,898,501	EEFSEC	eukaryotic elongation factor, selenocysteine-tRNA specific(EEFSEC)
rs7650602	3	141,147,414	ZBTB38	zinc finger and BTB domain containing 38(ZBTB38)
rs2293607	3	169,482,335	TERC	telomerase RNA component(TERC)
rs2736098	5	1,294,086	TERT	telomerase reverse transcriptase(TERT)
rs381949	5	1,322,468	CLPTM1L	CLPTM1 like(CLPTM1L)
rs4976790	5	177,968,915	COL23A1	collagen type XXIII alpha 1 chain(COL23A1)
rs200476	6	27,768,348	HIST1H2BL LOC100131289	histone cluster 1 H2B family member I(HIST1H2BL) uncharacterized LOC100131289(LOC100131289)
rs130067	6	31,118,511	CCHCR1	coiled-coil alpha-helical rod protein 1(CCHCR1)
rs3129859	6	32,400,939	BTNL2	butyrophilin like 2(BTNL2)
			HLA-DRA	major histocompatibility complex, class II, DR alpha(HLA-DRA)
rs9472120	6	43,709,785	MRPS18A	mitochondrial ribosomal protein S18A(MRPS18A)
			VEGFA	vascular endothelial growth factor A(VEGFA)
rs339331	6	117,210,052	RFX6	regulatory factor X6(RFX6)
rs35389879	7	21,812,043	DNAH11	dynein axonemal heavy chain 11(DNAH11)
rs17621345	7	40,875,192	SUGCT	succinyl-CoA:glutarate-CoA transferase(SUGCT)
rs6955627	7	92,577,760	LOC101927497 SAMD9	uncharacterized LOC101927497(LOC101927497) sterile alpha motif domain containing 9(SAMD9)
rs2928679	8	23,438,975	NKX3-1 SLC25A37	NK3 homeobox 1(NKX3-1) solute carrier family 25 member 37(SLC25A37)
rs1016343	8	128,093,297	PRNCR1	prostate cancer associated non-coding RNA 1(PRNCR1)
rs620861	8	128,335,673	CASC21	cancer susceptibility candidate 21 (non-protein coding)(CASC21)
rs6983267	8	128,413,305	CCAT2	colon cancer associated transcript 2 (non-protein coding)(CCAT2)
rs11986220	8	128,531,689	CASC11 CASC8	cancer susceptibility candidate 11 (non-protein coding)(CASC11) cancer susceptibility candidate 8 (non-protein coding)(CASC8)
rs4451364	9	109,532,734	LINC01505 ZNF462	long intergenic non-protein coding RNA 1505(LINC01505) zinc finger protein 462(ZNF462)
rs10788167	10	123,054,018	FGFR2 MIR5694	fibroblast growth factor receptor 2(FGFR2) microRNA 5694(MIR5694)
rs72878024	11	199,492	ODF3	outer dense fiber of sperm tails 3(ODF3)
rs12785905	11	66,951,965	KDM2A	lysine demethylase 2A(KDM2A)
rs878987	11	134,266,372	B3GAT1	beta-1,3-glucuronyltransferase 1(B3GAT1)
rs10845938	12	14,416,918	ATF7IP GRIN2B	activating transcription factor 7 interacting protein(ATF7IP) glutamate ionotropic receptor NMDA type subunit 2B(GRIN2B)
rs1270884	12	114,685,571	RBM19 TBX5	RNA binding motif protein 19(RBM19) T-box 5(TBX5)
rs8853	12	115,108,907	TBX3	T-box 3(TBX3)
rs1327653	13	51,076,440	DLEU1-AS1 ST13P4	DLEU1 antisense RNA 1(DLEU1-AS1) suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) pseudogene 4(ST13P4)
rs12913603	15	70,668,824	SALRNA3 TLE3	senescence associated long non-coding RNA 3(SALRNA3) transducin like enhancer of split 3(TLE3)
rs11863709	16	57,654,576	ADGRG1	adhesion G protein-coupled receptor G1(ADGRG1)
rs28709974	16	79,847,632	LINC01229 LOC102724084	long intergenic non-protein coding RNA 1229(LINC01229) uncharacterized LOC102724084(LOC102724084)
rs8052913	16	82,166,181	HSD17B2 MPHOSPH6	hydroxysteroid 17-beta dehydrogenase 2(HSD17B2) M-phase phosphoprotein 6(MPHOSPH6)
rs78378222	17	7,571,752	TP53	tumor protein p53(TP53)
rs72811270	17	12,585,459	LOC101928418	uncharacterized LOC101928418(LOC101928418)
rs11649743	17	36,074,979	HNF1B	HNF1 homeobox B(HNF1B)
rs9958656	18	19,904,144	CTAGE1 GATA6	cutaneous T-cell lymphoma-associated antigen 1(CTAGE1) GATA binding protein 6(GATA6)
rs28607662	18	53,230,859	TCF4	transcription factor 4(TCF4)
rs76765083	19	51,362,715	KLK3	kallikrein related peptidase 3(KLK3)
rs2427345	20	61,015,611	GATA5 RBBP8NL	GATA binding protein 5(GATA5) RBBP8 N-terminal like(RBBP8NL)
rs11701433	21	40,296,411	LOC400867	uncharacterized LOC400867(LOC400867)
rs58133635	22	40,471,188	LOC100130899 TNRC6B	uncharacterized LOC100130899(LOC100130899) trinucleotide repeat containing 6B(TNRC6B)
rs5919432	23	67,021,550	AR OPHN1	androgen receptor(AR) oligophrenin 1(OPHN1)

It is made available under a [CC-BY-NC 4.0 International license](#).

sTable 4. Enrichment analysis of nearest genes in the chromosomal regions associated with both BPH and PCa (6,879 genes in KEGG)

KEGG pathway (No. genes in the pathway)	No. (%) genes observed	Observed genes	P-Fisher	P-Benjamini
Prostate cancer (88)	5 (7.7%)	<i>AR, KLK3, TP53, FGFR2, NKX3-1</i>	4.10E-06	7.10E-03
Pathways in cancer (393)	6 (9.2%)	<i>AR, KLK3, TP53, FGFR2, NKX3-1, VEGFA</i>	6.50E-04	0.15
Systemic lupus erythematosus (134)	3 (4.6%)	<i>HIST1H2BL, HLA-DRA, GRIN2B</i>	6.50E-03	1.00
Maturity onset diabetes of the young (26)	2 (3.1%)	<i>RFX6, HNF1B</i>	2.50E-03	1.00
Huntington's disease (192)	3 (4.6%)	<i>DNAH11, TP53, GRIN2B</i>	0.017	1.00